<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04133376</url>
  </required_header>
  <id_info>
    <org_study_id>T30IP1013</org_study_id>
    <nct_id>NCT04133376</nct_id>
  </id_info>
  <brief_title>Electronic Hookah and Endothelial Cell Function</brief_title>
  <official_title>The Effects of Electronic Hookah on Endothelial Cell Function: The Role of Nicotine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tobacco Related Disease Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Electronic nicotine delivery systems (ENDS) are a new rapidly growing global epidemic. More
      recently, electronic (e-) hookahs, have increased in popularity in the United States, with
      the greatest uptake by young female adults, who endorse marketing claims that these products
      are safer alternatives to traditional flavored hookah tobacco smoking. Unlike other ENDS such
      as e-cigarettes, e-hookah bowls are used through traditional water-pipes, allowing the
      vapor—containing nicotine, propylene glycol, glycerin, and flavorings—to pass through a
      water-filled basin, potentially altering the vapor, before it is inhaled through the user's
      mouth. Contributing to e-hookah bowls' popularity is the belief that the flavored smoke is
      detoxified as it passes through the water-filled basin, rendering e-hookah a safer tobacco
      alternative. However, an e-hookah bowl delivers flavored nicotine by creating a vapor of fine
      particles and volatile organic compounds that could induce vascular toxicity. The objective
      of this project is to investigate the effects of e-hookah bowl inhalation on endothelial
      function, vascular biomarkers and volatile compounds; and molecular mechanisms underlying
      e-hookah induced endothelial injury using freshly harvested human endothelial cells with a
      specific role of nicotine. In a cross-over study design, the investigators will first assess
      endothelial function measured by brachial artery flow-mediated dilation and markers of
      oxidative stress and inflammation in 18 young healthy hookah smokers 21-39 years old, before
      and after two separate 30-minute e-hookah bowl inhalation sessions using one brand of
      nicotine-containing and nicotine-free e-hookah liquid and, for control comparison, before and
      after sham hookah smoking. Then, in freshly harvested venous endothelial cells the
      investigators will assess nitric oxide bioavailability, and expression of markers of
      inflammation and oxidative stress before and after the sessions. To compare specific
      exposures across conditions, the research team will measure changes in plasma nicotine, and
      highly specific urinary mercapturic acid metabolites of acrolein and benzene. This proposed
      study will provide critical scientific data on the impact of e-hookah inhalation on vascular
      health and mechanisms of exposure on known cardiac risk factors. Results will provide
      critical data to the FDA to inform the development of regulations specific to hookah.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Endothelial function</measure>
    <time_frame>30 minutes</time_frame>
    <description>∆Flow-Mediated Dilation (FMD), % from pre- to post- cuff occlusion performed before and after each exposure experiment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in biomarkers of oxidative stress and inflammation.</measure>
    <time_frame>30 minutes</time_frame>
    <description>∆plasma 8-iso-prostaglandin F2α before and after each exposure experiment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in biomarkers of oxidative stress and inflammation.</measure>
    <time_frame>30 minutes</time_frame>
    <description>∆plasma fibrinogen before and after each exposure experiment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in biomarkers of oxidative stress and inflammation.</measure>
    <time_frame>30 minutes</time_frame>
    <description>∆plasma oxidized LDL before and after each exposure experiment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in endothelial cell function</measure>
    <time_frame>30 minutes</time_frame>
    <description>∆nitric oxide bioavailability before and after each exposure experiment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in endothelial cell function</measure>
    <time_frame>30 minutes</time_frame>
    <description>∆nuclear factor-ĸB activation before and after each exposure experiment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in endothelial cell function</measure>
    <time_frame>30 minutes</time_frame>
    <description>∆nitrotyrosine before and after each exposure experiment.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Smoking</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Vascular Endothelial Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarkers of oxidative stress and inflammation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vascular endothelial cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Hookah Inhalation (+ nicotine)</intervention_name>
    <description>Participants will be instructed to inhale a typical 30-minute session of e-hookah containing nicotine</description>
    <arm_group_label>Biomarkers of oxidative stress and inflammation</arm_group_label>
    <arm_group_label>Vascular Endothelial Function</arm_group_label>
    <arm_group_label>Vascular endothelial cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Hookah Inhalation (- nicotine)</intervention_name>
    <description>Participants will be instructed to inhale a typical 30-minute session of e-hookah not containing nicotine</description>
    <arm_group_label>Biomarkers of oxidative stress and inflammation</arm_group_label>
    <arm_group_label>Vascular Endothelial Function</arm_group_label>
    <arm_group_label>Vascular endothelial cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Inhalation</intervention_name>
    <description>Participants will be instructed to inhale a 30-minute sham session</description>
    <arm_group_label>Biomarkers of oxidative stress and inflammation</arm_group_label>
    <arm_group_label>Vascular Endothelial Function</arm_group_label>
    <arm_group_label>Vascular endothelial cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  21-39 years old hookah smokers: smoked hookah &gt;12x in last 12 months

          -  no history of illicit drugs

          -  no evidence of cardiopulmonary disease by history/ physical

          -  no diabetes: fasting blood glucose &lt;100 mg/dl

          -  BP&lt;140/90mmHg

          -  resting HR&lt;100 bpm

          -  BMI&lt;30kg•m2

          -  no prescription medication

        Exclusion Criteria:

          -  exhaled CO&gt;10 ppm (smoking non-abstinence)

          -  positive pregnancy test

          -  psychiatric illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Rezk-Hanna, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven Mann, BA</last_name>
    <phone>310-562-4348</phone>
    <email>Stevenmann@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Westwood</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Mann, BA</last_name>
      <email>Stevenmann@mednet.ucla.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2019</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Mary Rezk-Hanna, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

